Advanced Therapies 2020 – VJRegenMed

LUMEVOQ: gene therapy for Leber hereditary optic neuropathy

admin_vjr_user — Wed, 09 Sep 2020 13:05:20 +0000

Magali Taiel, MD, of GenSight Biologics, Paris, France, discusses LUMEVOQ gene therapy for patients with Leber hereditary optic neuropathy, a mitochondrial inherited form of vision loss. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

World’s first off-the-shelf NK cellular immunotherapy

admin_vjr_user — Tue, 08 Sep 2020 16:05:35 +0000

Troels Jordansen, Glycostem Therapeutics, Oss, The Netherlands, discusses the development of the world’s first off-the-shelf NK cellular immunotherapy in acute myeloid leukemia patients and subsequent clinical trials involving oNKord® cellular therapy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

RESCUE & REVERSE: long-term follow ups of LUMEVOQ gene therapy

admin_vjr_user — Tue, 08 Sep 2020 16:05:35 +0000

Magali Taiel, MD, of GenSight Biologics, Paris, France, discusses the long-term follow-up results of RESCUE and REVERSE, two Phase III clinical trials evaluating LUMEVOQ gene therapy in patients with Leber hereditary optic neuropathy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

4-year Horizon 2020 ITN-Marie Curie training network

admin_vjr_user — Tue, 08 Sep 2020 16:05:35 +0000

Troels Jordansen, of Glycostem Therapeutics, Oss, The Netherlands, discusses the 4-year Horizon 2020 ITN-Marie Curie training programme aiming to develop novel methods to manufacture tumor reactive NK cells.This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).